Quick Answer
Tesamorelin is best understood on a months-long timeline. The major studies used 26-week main phases, and longer-term data followed treatment over 52 weeks. The strongest visible and measured results are not built around a quick two-week cycle.
The most useful cycle-length takeaway is that tesamorelin's effect appears active during continued exposure. In extension data, visceral fat reaccumulated after discontinuation, which means the body-composition benefit should not be framed as a permanent one-cycle fix.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileWhy Cycle Length Matters
Tesamorelin works through growth-hormone-releasing hormone signaling. That mechanism is not the same as an acute stimulant or appetite suppressant. The clinical outcomes that made tesamorelin famous were measured over months: visceral-fat reduction, waist-profile improvement, and sustained body-composition effects during continued use.
That is why short-cycle language can be misleading. Tesamorelin is not best judged by what happens in a few days. It is a gradual body-composition peptide.
What The Studies Used
The major randomized trial used a 26-week main phase, followed by a 26-week extension. Participants initially received tesamorelin or placebo, then some continued tesamorelin while others switched.
That design gives readers two useful timelines: the six-month change window and the one-year continuation window.
| Timeline | What it tells readers |
|---|---|
| 26 weeks | Main clinical window where meaningful visceral-fat reductions were measured. |
| 52 weeks | Continued treatment sustained visceral-fat reduction in extension data. |
| After stopping | VAT reaccumulated in people who discontinued tesamorelin. |
| Daily exposure | Trials and label context center on once-daily subcutaneous use. |
Six Months Is The Key Evidence Window
At six months, the major trial reported a 10.9% visceral adipose tissue reduction with tesamorelin versus 0.6% with placebo. Waist circumference and waist-to-hip ratio also improved.
That makes 26 weeks the most defensible evidence window for before-and-after expectations. It is long enough for measurable body-composition change and short enough to be practical for readers trying to understand timelines.
One-Year Data Adds Context
The 52-week extension data showed sustained visceral-fat reduction around 18% in people who continued tesamorelin. Triglyceride improvements were also sustained in that study.
This is one of the strongest points in tesamorelin's favor. The data do not stop at a short proof of concept. The longer extension suggests that the visceral-fat effect can be maintained while treatment continues.
What Happens When Stopping
The same long-term study reported that visceral fat reaccumulated after discontinuation. This is not a reason to dismiss tesamorelin. It is a reason to set expectations correctly.
Tesamorelin appears to work while the signal is active. If the signal stops, the body can drift back toward its prior pattern. That is common for many body-composition interventions, but it is especially important for anyone thinking in cycles.
Cycle Length Versus Vial Planning
Research-product planning introduces a separate question: how long a vial lasts. That depends on vial size, reconstitution volume, final concentration, and the amount being measured. It is not the same as clinical cycle length.
Use the peptide calculatorCalculate concentration and syringe-unit math for research planning.Open calculatorPlanning A Longer Research Window
Longer timelines make supply planning less forgiving. A research listing should make vial amount, product name, documentation status, and shipping expectations easy to understand before anyone starts doing concentration math.
Tesamorelin Vendors For Research Planning
View all Tesamorelin vendors| Vendor | Country | Rating | COAs | Promo | Payment | Shipping | Website |
|---|---|---|---|---|---|---|---|
| LA Peptides | USA | 5.0 (1) | Yes | 10% off (AMINORANK) | Card, ACH | Fast shipping, International | Buy |
| NextGenPeps | USA | 5.0 (1) | Yes | 10% off (AMINORANK) | Card, ACH, Crypto | Fast shipping | Buy |
| Alpha Peptides | USA | 0.0 (0) | Yes | 10% off (AMINORANK) | Card | Standard | Buy |
| Ascension Peptides | USA | 0.0 (0) | Yes | 50% off (AMINORANK) | Card | Standard | Buy |
| BioCollex | USA | 0.0 (0) | Yes | 10% off (AMINORANK) | Not listed | International | Buy |
| Coastal Peptides | USA | 0.0 (0) | Yes | None listed | Card | Fast shipping, International | Buy |
FAQ
Is four weeks enough for tesamorelin?
The strongest clinical results were measured over months, especially at 26 weeks.
Why do people talk about 26-week tesamorelin cycles?
Because major studies used 26-week main phases and reported meaningful visceral-fat outcomes at that point.
Can tesamorelin be stopped after results?
Extension data showed visceral fat reaccumulation after discontinuation, so stopping can reduce the maintained effect.
Is cycle length the same as vial duration?
No. Cycle length is a timeline question. Vial duration is concentration and measurement math.